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Abstract 
 
Background: Previous studies have reported improvements in life expectancies of patients 
on antiretroviral treatment (ART) over time, but it is not clear whether these improvements 
are explained by changes in baseline clinical characteristics, longer duration on ART, or 
changes in clinical practices. 
Method: Two parametric survival models were fitted to mortality data from South African 
ART cohorts that had linked patient records to the national vital registration system. The first 
model estimated mortality by age, sex, cohort, baseline CD4 count, time since ART initiation 
and period of ART initiation; the second model included only age, sex, cohort and period of 
follow-up. Life expectancies were calculated from the estimated mortality rates. 
Results: The first model estimated little change in mortality over time: women starting ART 
at age 35, at CD4 counts of 200 cells/μl or higher, had life expectancies of 32.7 (95% CI: 
31.6-33.6), 32.4 (95% CI: 31.3-33.4) and 33.0 (95% CI: 32.0-34.1) in the 2001-2006, 2007-
2009 and 2010-2014 periods respectively. However, the second model estimated a significant 
improvement in life expectancy; for all women on ART at age 35, corresponding life 
expectancies were 13.0 (95% CI: 12.1-14.2), 20.4 (95% CI: 19.5-21.4) and 26.1 (95% CI: 
25.2-26.9) respectively. 
Conclusions: Although life expectancies in South African ART patients have improved over 
time, these improvements are not observed after controlling for changes in baseline CD4 
count and ART duration. This suggests that changes in clinical practice and programme scale 
have had little impact on ART mortality in South Africa.  
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Introduction 
Several recent studies have shown improving life expectancies over time, among adults 
receiving ART [1-4]. However, it is not yet clear to what extent this improvement is due to 
improvements in patient care, changes in baseline clinical characteristics and/or changes in 
average ART durations [5]. Because most previously-published analyses of life expectancy 
trends do not simultaneously control for changes over time in baseline CD4 distributions and 
changes in ART durations, the true extent to which clinical changes are leading to 
improvements in mortality is uncertain.  
 
In a previous analysis of life expectancies of adults starting ART in South Africa, we showed 
that life expectancies at the point of ART initiation were approximately 80% of those in HIV-
negative adults of the same age, if ART was initiated at CD4 counts >200 cells/μl [6]. 
However, this analysis was limited by lack of long-term follow-up data and the relatively 
small numbers of patients starting ART at higher CD4 counts. Life expectancy forecasts are 
sensitive to mortality estimates at longer ART durations, and it is therefore important to 
update these forecasts as more data become available on patients with longer follow-up 
durations.  
 
South Africa is in a unique position within Africa, being the only country with both a large 
HIV burden and a well-functioning death notification system, which is estimated to record 
around 95% of all adult deaths [7]. This makes it possible to obtain reasonably accurate 
estimates of mortality, which are not biased by the high loss to follow-up observed in many 
ART cohorts in developing countries [8]. This paper aims to produce updated estimates of 
life expectancies in South Africa and to test whether life expectancies of ART patients have 
improved after controlling for changes in baseline CD4 and ART duration. 
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Methods 
 
This analysis is based on eight South African cohorts providing ART to adults (listed in 
Table S1). All cohorts obtained ethical approval from relevant local institutions before 
contributing anonymized data to the collaborative analysis. In addition, the collaboration 
received ethical approval from the University of Cape Town Human Research Ethics 
Committee to receive and analyse these data. Each cohort linked patient records to the 
national vital registration system, for all patients who had a national identity number (ID), to 
determine their vital status (and date of death where relevant).  
 
Patients were included in the analysis if they were aged 15 or older at ART initiation and 
started ART in 2001 or later. Patients were excluded if they had a missing baseline CD4 
count or a viral load of <400 copies/ml prior to ART initiation. The analysis was limited to 
patients with recorded IDs; this restriction was introduced because of concern that some 
cohorts may have incorporated data from the vital registration system into patient records, 
which would invalidate the inverse probability weighting approach that was previously 
applied to account for differences in the recording of deaths between patients with and 
without IDs [6]. Patients with recorded IDs have previously been shown to be similar to 
patients without recorded IDs in their clinical and demographic characteristics, although the 
capturing of patient ID information has become more frequent in recent years [9]. 
 
Patients were considered dead if death was recorded on either the patient record system or the 
vital registration system (in the event of discrepancies in the recorded date of death, the date 
on the patient record was assumed to be correct). Observation time was calculated from the 
date when the patient first started ART. Observation was censored at the recorded date of 
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death or 30 days prior to the date on which the patient’s record was linked to the vital 
registration system, whichever date occurred first (the 30-day offset was included to reduce 
bias due to possible late registration of deaths). No censoring was applied if the patient 
interrupted ART, transferred to other ART services or did not return to the clinic, since the 
only outcome of interest was death after ART initiation, which could be determined from the 
vital registration system. 
 
The statistical approach to estimating life expectancy is the same as that described previously 
[6]. Briefly, two parametric relative survival models [10] were fitted to the mortality data to 
identify predictors of mortality in excess of that expected in HIV-negative South Africans 
[11]. In the first model, explanatory variables included cohort, age, baseline CD4 count 
(categorized as shown in Table S1), ART duration and period of ART initiation (three 
periods were defined, with cut-offs at the end of 2006 and 2009 to ensure similar proportions 
of patients in each period). In the second model, to be consistent with the approach adopted in 
other analyses of life expectancy trends [1-4], explanatory variables included cohort, age and 
period of ART follow-up (defined by the same cut-offs). The relative survival models were 
fitted separately for males and females, and (in the first model) for periods ≤ 12 months and > 
12 months after ART initiation. Parametric bootstrap sampling was used to calculate 95% 
confidence intervals. For each bootstrap sample, tables of age-specific mortality rates were 
calculated (for each integer ART duration in the case of the first model), and from these 
mortality tables, life expectancies were calculated for all age, sex, cohort, CD4 and period 
categories. Life expectancies were averaged across the eight cohorts and across 1000 
bootstrap samples. Statistical analyses were performed in STATA 13.0 (StataCorp) and C++. 
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Sensitivity analyses were performed to assess the effect of including patients with missing 
baseline CD4 values, assigning CD4 values using multiple imputation [12]. Sensitivity 
analyses also assessed Cox proportional hazard models. 
 
Results 
 
From an initial database of 106 498 patients, 37 383 (35%) were excluded due to absence of 
IDs, 13 542 (13%) were excluded due to missing baseline CD4 measures and 3 084 (3%) 
were excluded due to baseline viral load levels below 400 copies/ml. Analyses were 
performed on the remaining 52 489 patients. Baseline characteristics are summarized in 
Table S1: http://links.lww.com/QAD/A950  29.1% of patients started ART in the 2001-2006 
period, 42.4% started ART in the 2007-2009 period, and the remaining 28.5% started ART in 
2010 or later. Patients were followed for a total of 204 508 person years (average follow-up 
duration of 3.90 years). A total of 8 376 deaths occurred, yielding a crude mortality rate of 
41.0 per 1000 person years.  
 
The coefficients of the first relative survival model are summarized in Supplementary Table 
S2. http://links.lww.com/QAD/A950 After adjusting for differences in baseline covariates and 
differences in treatment durations, HIV-related mortality rates in patients starting ART before 
2007 were similar to those in patients starting ART in the 2007-2009 and 2010-2014 periods. 
Men starting ART at age 35, at CD4 counts of 200 cells/μl or higher, had life expectancies of 
26.1 years (95% CI: 24.9-27.3), 26.4 years (95% CI: 25.2-27.5) and 26.7 years (95% CI: 
25.3-28.0) in the 2001-2006, 2007-2009 and 2010-2014 periods respectively (80-82% of 
HIV-negative life expectancy). The corresponding life expectancies for women were 32.7 
years (95% CI: 31.6-33.6), 32.4 years (31.3-33.4) and 33.0 years (95% CI: 32.0-34.1) 
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respectively (82-84% of HIV-negative life expectancy). Similarly, no trends in life 
expectancy were apparent when considering other baseline CD4 categories and baseline ages 
(Figure 1).  
 
In the second survival model, which did not control for ART duration or baseline CD4 count, 
HIV-related mortality rates declined significantly in successive follow-up periods (Table S3, 
http://links.lww.com/QAD/A950). As a result, life expectancies increased over time (Figure 2). 
For men on ART at age 35, life expectancies increased from 9.9 (95% CI: 9.2-10.6) in 2001-
2006 to 15.9 (95% CI: 15.3-16.6) in 2007-2010 and 21.1 (95% CI: 20.3-21.8) in 2010-2014. 
Corresponding estimates for women aged 35 were 13.0 (95% CI: 12.1-14.2), 20.4 (95% CI: 
19.5-21.4) and 26.1 (95% CI: 25.2-26.9) respectively. 
 
Results from the first model were similar when patients with missing baseline CD4 values 
were included in the analysis, with imputation of missing CD4 values (Supplementary Table 
S4, http://links.lww.com/QAD/A950). No trend in mortality was observed when fitting Cox 
proportional hazards models that more accurately controlled for baseline CD4 count and ART 
duration (Supplementary Table S5, http://links.lww.com/QAD/A950).  
 
Discussion 
 
This analysis shows that life expectancy estimates are sensitive to the calculation method 
used, and care is therefore required in the interpretation of life expectancy statistics. The first 
model yields a prognostic measure for a patient starting ART with a given CD4 count, while 
the second model is a summary indicator of mortality among all patients on ART in a 
particular calendar period. Consistent with other studies that have used the second model  [1-
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4], our analysis shows an improvement in aggregate mortality levels in ART patients. 
However, after controlling for changes over time in baseline CD4 count and ART duration, 
the second model suggests no improvement in life expectancy. The lack of improvement 
might be considered surprising in view of various improvements in clinical practices. These 
include the change in South African ART guidelines in 2010 to recommend the use of 
tenofovir instead of stavudine in first-line drug regimens [13]; the introduction of fixed dose 
combination ART in 2013, which has been shown to be associated with improved adherence 
and virological suppression [14]; and the introduction of adherence clubs since 2011 in some 
centres [15]. It is possible that these gains may have been offset by increases in loss to 
follow-up [16], and possible reductions in quality of care as programmes have expanded in 
size.  
 
The results from the first model reaffirm our previous findings of near-normal life 
expectancies in South African patients starting ART at CD4 counts above 200 cells/μl [6]. 
This analysis improves on our previous analysis by including a broader range of ART cohorts 
(two additional cohorts added to the six cohorts considered previously), a greater number of 
patients (52 489 patients compared to 37 740 previously) and more than double the average 
length of observation (3.90 years compared to 1.84 years previously).  
 
This study is limited by a lack of reliable data on the vital status of patients without IDs. Most 
ID information is missing because it was not requested, but a substantial proportion of those 
without ID information are individuals who do not have South African IDs, many of them 
foreign nationals. Although previous studies have shown that patients with recorded IDs are 
similar to those without in terms of demographic and clinical characteristics [9], we cannot 
exclude the possibility that patients without IDs may have different mortality levels. Another 
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limitation is that the IeDEA cohorts might not be typical of the South African ART 
programme generally, particularly as most cohorts are based in urban areas. The 
generalizability of these findings to other settings within South Africa is therefore unclear. 
 
 In summary, previously-observed improvements if life expectancies of patients on ART, 
over time, might be explained mostly by changes in baseline CD4 count and ART duration. 
In South Africa there is little evidence to suggest that life expectancy improvements are 
attributable to changes in clinical practice. 
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Figure legends 
 
Figure 1: Life expectancies from time of ART initiation (Model 1), compared to HIV-
negative life expectancies 
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Figure 2: Life expectancies of patients on ART by period of follow-up (Model 2, not 
controlling for baseline CD4 count and ART duration)  
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